Compare Cassava Sciences Inc (FLNA) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Moody's Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Moody's Corporation trades at $513.51 (market cap $88.12B). The key difference: Moody's Corporation is far larger — about 1658.3× Cassava Sciences Inc's market cap, and Moody's Corporation pays a 0.82% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MCO | |
|---|---|---|
Market Cap | $53.14M | $88.12B |
Sector | Health | Financials |
52-Week High | $4.64 | $539.61 |
52-Week Low | $1.09 | $412.23 |
Enterprise Value | -$33.43M | $93.92B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Moody's Corporation (MCO) trades at $494.73, down 0.2% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with revenue growth to $7.72B in 2025 and a robust net income margin of 31.69%. Recent earnings have consistently beaten expectations, and analyst consensus remains positive with a $539.40 price target. The stock is supported by Moody's dominant position in credit ratings and strategic AI integration initiatives.
Outlook remains favorable given Moody's oligopoly position, recurring revenue model, and 17-year dividend growth streak. Key opportunities include leveraging AI capabilities and benefiting from corporate debt issuance cycles. Risks include valuation concerns with a P/E of 36.19, regulatory scrutiny of credit rating agencies, and potential economic slowdowns affecting debt markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
